Researchers from Witchita Kansas examined the metabolic component of CFS, by determined serum NAD(P)H levels in 44 CFS patients and 30 healthy control subjects by measuring serum fluorescence emission at 450 nm. It was directly correlated with serum coenzyme Q10 levels and inversely correlated with urine hydroxyhemopyrrolin-2-one (HPL) levels.
Based on these findings, they propose the use of serum NAD(P)H, measured as an intrinsic serum fluorescence emission, to monitor metabolism and fatigue status in people with CFS.
Following patient NAD(P)H levels over time may aid in selecting therapeutic strategies and monitoring treatment outcome.
